Evidence supporting the use of: Insulin-like growth factor
For the health condition: Strokes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Insulin-like growth factor (IGF), particularly IGF-1, has been investigated as a potential therapeutic agent for stroke based on its neuroprotective and neuroregenerative properties observed in preclinical studies. Experimental data from animal models of ischemic stroke suggest that IGF-1 administration can reduce neuronal death, limit infarct size, and improve functional recovery. Mechanistically, IGF-1 is thought to exert its effects by inhibiting apoptosis, promoting angiogenesis, reducing inflammation, and enhancing neurogenesis. These findings are supported by a number of preclinical studies, but translation to human clinical trials remains limited.

To date, there is only early-phase clinical data regarding IGF-1 in stroke, and its use is not an established or approved therapy for this condition. Small pilot studies and case reports have explored IGF-1’s safety profile and potential effects, but robust randomized controlled trials are lacking. Systematic reviews note the promise of IGF-1 as a neuroprotective agent but consistently emphasize the need for more rigorous clinical testing to confirm efficacy and safety in humans.

In conclusion, while there is mechanistic and preclinical scientific rationale for IGF-1 use in stroke, clinical evidence in humans is limited and inconclusive. Current guidelines do not recommend IGF-1 for stroke treatment outside of clinical trials.

More about Insulin-like growth factor
More about Strokes

Products containing Insulin-like growth factor

We currently have no products on Caring Sunshine that contain this ingredient.